9EO0 image
Entry Detail
PDB ID:
9EO0
Title:
Small-Molecule Inhibitors of Programmed Cell Death-1/Programmed Death-Ligand 1
Biological Source:
Source Organism:
Host Organism:
PDB Version:
Deposition Date:
2024-03-14
Release Date:
2024-06-19
Method Details:
Experimental Method:
Resolution:
2.50 Å
R-Value Free:
0.30
R-Value Work:
0.25
Space Group:
P 1 21 1
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:Programmed cell death 1 ligand 1
Chain IDs:A, B, C, D, E, F
Chain Length:131
Number of Molecules:6
Biological Source:Homo sapiens
Primary Citation
Nonsymmetrically Substituted 1,1'-Biphenyl-Based Small Molecule Inhibitors of the PD-1/PD-L1 Interaction.
Acs Med.Chem.Lett. 15 828 836 (2024)
PMID: 38894909 DOI: 10.1021/acsmedchemlett.4c00042

Abstact

Therapeutic antibodies directed against either programmed cell death-1 protein (PD-1) or its ligand PD-L1 have demonstrated efficacy in the treatment of various cancers. In contrast with antibodies, small molecules have the potential for increased tissue penetration; better pharmacology; and therefore, improved antitumor activity. A series of nonsymmetric C2 inhibitors were synthesized and evaluated for PD-1/PD-L1 interaction inhibition. These compounds induced PD-L1 dimerization and effectively blocked PD-L1/PD-1 interaction in a homogeneous time-resolved fluorescence (HTRF) assay with most inhibitors exhibiting IC50 values in the single-digit nM range and below. Their high inhibitory potency was also demonstrated in a cell-based coculture PD-1 signaling assay where 2 exhibited an EC50 inhibitory activity of 21.8 nM, which approached that of the PD-L1 antibody durvalumab (EC50 = 0.3-1.8 nM). Structural insight into how these inhibitors interact with PD-L1 was gained by using NMR and X-ray cocrystal structure studies. These data support further preclinical evaluation of these compounds as antibody alternatives.

Legend

Protein

Chemical

Disease

Primary Citation of related structures